AEMD — Aethlon Medical Income Statement
0.000.00%
- $4.13m
- $0.37m
- 10
- 32
- 24
- 10
Annual income statement for Aethlon Medical, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
C2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.659 | 0.294 | 0.574 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 8.55 | 10.7 | 12.6 | 12.6 | 9.34 |
Operating Profit | -7.89 | -10.4 | -12 | -12.6 | -9.34 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -7.89 | -10.4 | -12 | -12.2 | -13.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -7.89 | -10.4 | -12 | -12.2 | -13.4 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -7.89 | -10.4 | -12 | -12.2 | -13.4 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.89 | -10.4 | -12 | -12.2 | -13.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -52.2 | -56.5 | -46.3 | -38.9 | -8.58 |